BNT3214 / BioNTech - LARVOL DELTA

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=533 | Not yet recruiting | Sponsor: BioNTech SE

First-in-human • New P1/2 trial • Oncology • Solid Tumor